Takeda Pharmaceutical (TAK) Assets Average (2019 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Assets Average of $98.6 billion for Q2 2026, up 3.68% year-over-year from $95.1 billion in Q2 2025, and down 0.93% quarter-over-quarter from $99.5 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Assets Average (2019 - 2026) Analysis & Trends
Takeda Pharmaceutical's Assets Average history runs 8 years deep, the most recent figure standing at $98.6 billion for Q2 2026.
- In Q2 2026, Assets Average rose 3.68% year-over-year to $98.6 billion; the TTM figure through Jun 2026 stood at $98.6 billion (up 3.68% YoY), while the FY2026 annual figure was $98.3 billion, down 0.87% from the prior year.
- Assets Average for Q2 2026 stood at $98.6 billion, down from $99.5 billion in the prior quarter.
- The five-year high for Assets Average was $112.6 billion in Q1 2022, with the low at $95.1 billion in Q2 2025.
- The 5-year median for Assets Average is $100.1 billion (2023), against an average of $101.8 billion.
- The sharpest annual moves came in 2022 and 2026: Assets Average declined 10.89% in 2022, then advanced 3.68% in 2026.
- Takeda Pharmaceutical's Assets Average stood at $100.6 billion in 2022, then dropped by 1.0% to $99.6 billion in 2023, then decreased by 1.07% to $98.5 billion in 2024, then climbed by 0.64% to $99.2 billion in 2025, then declined by 0.58% to $98.6 billion in 2026.
- Business Quant data shows TAK's Assets Average at $98.6 billion in Q2 2026, $99.5 billion in Q1 2026, and $99.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 5.97 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 4.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.59 Bn |
| Mar 31, 2026 | 99.52 Bn |
| Dec 31, 2025 | 99.17 Bn |
| Sep 30, 2025 | 97.50 Bn |
| Jun 30, 2025 | 95.09 Bn |
| Mar 31, 2025 | 96.38 Bn |
| Dec 31, 2024 | 98.53 Bn |
| Sep 30, 2024 | 100.97 Bn |
| Jun 30, 2024 | 103.10 Bn |
| Mar 31, 2024 | 99.09 Bn |
| Dec 31, 2023 | 99.60 Bn |
| Sep 30, 2023 | 105.46 Bn |
| Jun 30, 2023 | 106.73 Bn |
| Mar 31, 2023 | 100.56 Bn |
| Dec 31, 2022 | 100.61 Bn |
| Sep 30, 2022 | 107.20 Bn |
| Jun 30, 2022 | 111.08 Bn |
| Mar 31, 2022 | 112.55 Bn |
| Dec 31, 2021 | 112.90 Bn |
| Sep 30, 2021 | 114.86 Bn |